Thursday, September 04, 2025 1:20:53 PM
Whatever the real financials around the specials are. It totally sucked for complete lack of transparency to us NW longs of the specials commercials from having it go thru Advent, even though there may have been very legit legal reasons for it at the time. Now there will be mixed sources of revenue for NW and they no doubt like it for legit secrecy of cogs purposes for competitive reasons that we will not be able to know how the overall revenue comprises the different streams. It would be much better for shareholders for that to be made quite clear but that is not LP's style.
It will be hard to know how low if the initial dc-vaxl commercialization stream is very low for however many quarters. Maybe that's good for the stock price if it's very low for very many quarters but I'd sure like to know that. Anyway, it's putting the cart before the horse here to even assume the approval is certain. If it is, the stock sure doesn't know it yet, sigh. It would have been nice to know more about the specials program than we could see in the tiny revenue that was dribbling in to NW, assuming there was more to it than it appeared.
It will be hard to know how low if the initial dc-vaxl commercialization stream is very low for however many quarters. Maybe that's good for the stock price if it's very low for very many quarters but I'd sure like to know that. Anyway, it's putting the cart before the horse here to even assume the approval is certain. If it is, the stock sure doesn't know it yet, sigh. It would have been nice to know more about the specials program than we could see in the tiny revenue that was dribbling in to NW, assuming there was more to it than it appeared.
Recent NWBO News
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
